Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
2252 Welsch Industrial Court, Building A, St. Louis, MO, 63146, US
Why pharma needs automated AI security now.
By: Frank Balonis
Forms a rare tumor business for Merck KGaA, Darmstadt, Germany, including SpringWorks’ portfolio and pimicotinib.
By: Charlie Sternberg
The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.
By: Rachel Klemovitch
It is the only ready-to-use liquid immunoglobulin therapy with (IgA) content and is set for commercialization in 2026.
The company’s label updates are for its CAR T cell therapies, Breyanzi and Abecma.
This strategic partnership provides end-to-end visibility and best-in-class track and trace for Praxis’s customer base.
Precision may also be eligible to receive a Priority Review Voucher upon FDA approval of PBGENE-DMD.
GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered at home.
Claims that knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers not authorized or inspected by the FDA.
Aversa Fentanyl combines Nutriband’s Aversa abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch.
The ribbon cutting ceremony was held on June 17th with Ferring executives and a few government officials.
Merck also introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1.
Ibtrozi is a next-generation oral treatment for advanced ROS1-positive non-small cell lung cancer.
Partnership includes joint research, technology transfer, and co-development of lead candidates.
Becomes the first and only non-invasive disease-modifying treatment available for people living with spinal muscular atrophy.
Industry experts weigh in on current trends, challenges, and the future of the cell and gene therapy CDMO market.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
